As global interest in herbal medicines continues to grow, only a limited number of products are developed with rigorous scientific methods and supported by strong clinical evidence. DLBS addresses this gap through the development of Integrative Modern Natural Medicines—therapeutics based on defined bioactive fractions with clear mechanisms of action and clinically validated efficacy (phytopharmaceuticals) in accordance with Good Clinical Practice. This commitment was showcased by DLBS at the Convention on Pharmaceutical Ingredients (CPHI) in Frankfurt, Germany, on 28–30 October 2025.
The event was attended by Dexa Group CEO, Mr. Ferry Soetikno, Mrs. Gracianti Soetikno (Commissioner of Dexa Group), Ms. Tifanny Robyn Soetikno (Head of Digital Ecosystem Development Singapore, Dexa International Business), as well as directors and management representatives from across Dexa Group.
Indonesia is one of the world’s richest nations in natural resources, particularly medicinal plants. However, only a small portion of these resources have been successfully transformed into standardized products that meet regulatory requirements. DLBS aims to change this by advancing innovations derived from Indonesia’s biodiversity that are reproducible, mechanism-based, and clinically validated—ensuring that these products meet global standards and expectations.
Three scientific innovations stood out at CPHI Frankfurt.
Inlacin, supported by reputable scientific publications, demonstrated meaningful improvements in insulin sensitivity.
Redacid, presented a standardized cinnamon-derived bioactive fraction for managing dyspepsia.
Veprolin, showcased advancements in hepatoprotective research amid the growing prevalence of metabolic liver disease, which now affects one in four adults worldwide.
With its capabilities in molecular discovery, clinical validation, and multi-billion-unit manufacturing capacity across Dexa Group, DLBS is positioning Indonesia as one of the most credible players in the global development of evidence-based natural medicines.
This represents the future of modern natural therapeutics: transparent mechanisms, defined active molecules, and clinically validated outcomes. DLBS stands at the forefront of this movement—beginning in Indonesia and moving toward global markets.